Fairooz Kabbinavar

Fairooz Kabbinavar

UNVERIFIED PROFILE

Are you Fairooz Kabbinavar?   Register this Author

Register author
Fairooz Kabbinavar

Fairooz Kabbinavar

Publications by authors named "Fairooz Kabbinavar"

Are you Fairooz Kabbinavar?   Register this Author

83Publications

2405Reads

13Profile Views

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

N Engl J Med 2018 12 25;379(23):2220-2229. Epub 2018 Sep 25.

From Vanderbilt University Medical Center (L. Horn) and Sarah Cannon Research Institute-Tennessee Oncology (M.L.J.), Nashville; Mayo Clinic, Rochester, MN (A.S.M.); Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock (A. Szczęsna), and Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warsaw (M.K.) - both in Poland; Thomayerova Nemocnice, Pneumologická Klinika 1.LF UK, Prague, Czech Republic (L. Havel); the Department of Respiratory and Critical Care Medicine (M.J.H.) and the 2nd Department of Respiratory and Critical Care Medicine (F.H.), Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology-Sozialmedizinisches Zentrum Baumgartner Höhe, Otto-Wagner-Spital, Vienna; Semmelweis Egyetem ÁOK, Pulmonológiai Klinika, Budapest, Hungary (G.L.); the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo (M.N.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany (M.R.); State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.), and F. Hoffmann-La Roche, Shanghai (J.L.) - both in China; Genentech, South San Francisco, CA (S.L., D.S.S., B.D., A.L.-C., F.K., W.L., A. Sandler); and Georgetown University, Washington DC (S.V.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1809064
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1809064DOI Listing
December 2018

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

J Clin Oncol 2017 Jun 17;35(17):1929-1937. Epub 2017 Apr 17.

Lindsay A. Renfro, Axel Grothey, and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Richard M. Goldberg, The Ohio State University, Columbus, OH; Alberto Sobrero, Ospedale San Martino, Genoa; Alfredo Falcone, University Hospital of Pisa, Pisa, Italy; Richard Adams, Cardiff University, Cardiff; Matthew T. Seymour, St James's Hospital and University of Leeds, Leeds, United Kingdom; Volker Heinemann, University of Munich, Munich; Hans-Joachim Schmoll, University Clinic Halle (Saale), Halle; Rainer Porschen, Klinikum Bremen-Ost Klinik für Innere Medizin, Bremen; Carsten Bokemeyer, University Hospital, Hamburg-Eppendorf, Germany; Jean-Yves Douillard, Centre René Gauducheau, Nantes; Christophe Tournigand, University of Paris Est Creteil; Christophe Tournigand, Assistance Hopitaux Publique de Paris Henri-Mondor Hospital, Créteil; Benoist Chibaudel and Aimery de Gramont, Franco-British Institute, Levallois-Perret, France; Herbert Hurwitz, Duke University Medical Center, Durham, NC; Charles S. Fuchs; Dana-Farber Cancer Institute, Boston, MA; Eduardo Diaz-Rubio, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain; Paulo M. Hoff, Hospital Sírio-Libanês and University of São Paulo, São Paulo, Brazil; Fairooz F. Kabbinavar and J. Randolph Hecht, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA; Niall C. Tebbutt, Austin Health, Heidelberg, Victoria, Australia; Cornelis J.A. Punt, University of Amsterdam, Amsterdam, the Netherlands; John Souglakos, University of Crete, Heraklion, Greece; Eric Van Cutsem, University Hospital Leuven, Leuven, Belgium; and Leonard Saltz, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.5771DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466009PMC
June 2017

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.

Onco Targets Ther 2016 30;9:7275-7283. Epub 2016 Nov 30.

Department of Medicine; Department of Hematology and Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S109186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138047PMC
November 2016

Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies.

Crit Rev Oncol Hematol 2015 Dec 20;96(3):527-33. Epub 2015 Jul 20.

University of California, Los Angeles, 924 Westwood Blvd. Suite 1050, Los Angeles, CA 90023-7207, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2015.07.009DOI Listing
December 2015

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.

J Clin Oncol 2015 Dec 2;33(34):4093-8. Epub 2015 Nov 2.

Yongli Ji, Steven Grunberg, and Claire Verschraegen, University of Vermont Cancer Center, Burlington, VT; Cathryn Rankin, SWOG Statistical Center, Seattle, WA; Andy E. Sherrod, Jamshid Ahmadi, and Christy A. Russell, University of Southern California; Fairooz F. Kabbinavar, University of California Los Angeles, Los Angeles, CA; Jeannette J. Townsend, University of Utah Medical Center, Salt Lake City, UT; Lynn G. Feun, University of Miami, Miami, FL; Ruth K. Fredericks, University of Mississippi Medical Center, Jackson, MS; Keith J. Stelzer, Celilo Cancer Center, the Dalles, OR; and Anne Schott, University of Michigan, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.6490DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669593PMC
December 2015

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

J Clin Oncol 2015 Jan 10;33(1):22-8. Epub 2014 Nov 10.

Qian Shi, Axel Grothey, and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Aimery de Gramont and Benoist Chibaudel, Hospital Saint Antoine; Christophe Tournigand, Université Paris Est Créteil, Paris; Jean-Yves Douillard, Institute of Cancer Research in Western, St Herblain, France; John Zalcberg, Monash University; Niall C. Tebbutt, Austin Health, Melbourne, Victoria, Australia; Hans-Joachim Schmoll, Martin-Luther University, Halle; Rainer Porschen, Klinikum Bremen-Ost, Bremen; Volker Heinemann, University of Munich, München; Carsten Bokemeyer, University Hospital, Hamburg-Eppendorf, Germany; Matthew T. Seymour, Cancer Research UK Clincal Center, Leeds; Richard Adams, Cardiff University, Cardiff, United Kingdom; Leonard Saltz, Memorial Sloan-Kettering Cancer Center, New York, NY; Richard M. Goldberg, Ohio State University, Columbus, OH; Cornelis J.A. Punt, Academic Medical Center, Amsterdam, the Netherlands; Paulo M. Hoff, Hospital Sírio-Libanês, Sao Paulo, Brazil; Joel Randolph Hecht and Fairooz F. Kabbinavar, University of California at Los Angeles, Los Angeles, CA; Herbert Hurwitz, Duke University, Durham, NC; Eduardo Díaz-Rubio, Hospital Clinico San Carlos, Madrid, Spain; Charles Fuchs, Dana-Farber Cancer Institute, Boston, MA; John Souglakos, University of Crete, Heraklion, Greece; Alfredo Falcone, University of Pisa, Pisa, Italy; Eric Van Cutsem, University Hospital Gasthuisberg, Leuven; and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.5887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482837PMC
January 2015

Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).

J Thorac Oncol 2014 Sep;9(9):1411-7

*University of California Los Angeles, Los Angeles, CA; †Kaiser Permanente Northern CA, Antioch, CA; ‡Sarah Cannon Research Institute, Nashville, TN; §Northwest Medical Specialties, Tacoma, WA; ‖Sibley Memorial Hospital, Washington, DC; ¶Integrated Community Oncology Network, Jacksonville, FL; #The Mark H. Zangmeister Center, Columbus, OH; **Florida Cancer Specialists, Bonita Springs, FL; ††Arch Medical Services Inc., The Center for Cancer Care and Research, Saint Louis, MO; ‡‡National Taiwan University, Taipei, Taiwan; §§F. Hoffmann-La Roche Ltd., Basel, Switzerland; ‖‖Genentech Inc., South San Francisco, CA; ¶¶Weill Cornell Medical College and Thoracic Oncology Service, New York, NY; and ##Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000274DOI Listing
September 2014

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

J Clin Oncol 2013 Nov 7;31(31):3926-34. Epub 2013 Oct 7.

Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA; Fairooz Kabbinavar, University of California Los Angeles, Translational Oncology Research International, Los Angeles; Louis Fehrenbacher, Kaiser Permanente Northern California, Vallejo; Chin-Yu Lin and Chris Bowden, Genentech, South San Francisco; Jonathan Polikoff, Southern California Permanente Medical Group, San Diego, CA; John Hainsworth, Sarah Cannon Research Institute, Nashville, TN; Saifuddin Kasubhai, Northwest Medical Specialties, Tacoma, WA; Bruce Kressel, Sibley Memorial Hospital, Washington, DC; Thomas Marsland, Integrated Community Oncology Network, Orange Park; Mark Rubin, Florida Cancer Specialists, Fort Myers, FL; Taral Patel, The Mark H. Zangmeister Center, Columbus, OH; Leonard White, Arch Medical Services, The Center for Cancer Care and Research, Saint Louis, MO; Vincent Miller, Weill Cornell Medical College and Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; and James Chih-Hsin Yang, National Taiwan University, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.3983DOI Listing
November 2013

Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.

Cancer 2013 Apr 18;119(8):1547-54. Epub 2013 Jan 18.

Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27947DOI Listing
April 2013

Systemic therapy for metastatic renal cell carcinoma: a review and update.

Rev Urol 2012 ;14(3-4):65-78

Institute of Urologic Oncology, Department of Urology, The David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602729PMC
March 2013

Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma.

Cancer 2012 Dec 17;118(23):5777-82. Epub 2012 May 17.

Department of Urology, Institute of Urologic Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095-7384, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.27607
Publisher Site
http://dx.doi.org/10.1002/cncr.27607DOI Listing
December 2012

Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.

Eur Urol 2012 May 18;61(5):888-95. Epub 2012 Jan 18.

Institute of Urologic Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2012.01.012DOI Listing
May 2012

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.

Eur J Cancer 2012 May 15;48(8):1126-32. Epub 2012 Mar 15.

Department of Medicine, Division of Hematology & Oncology, University of California at Los Angeles, 924 Westwood Blvd, Los Angeles, CA 90095-7207, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049120020
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2012.02.052DOI Listing
May 2012

Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival.

Cancer 2012 Apr 25;118(7):1795-802. Epub 2011 Aug 25.

Institute of Urologic Oncology, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, California 90095-7207, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26453DOI Listing
April 2012

The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma.

J Urol 2011 Dec 19;186(6):2168-74. Epub 2011 Oct 19.

Institute of Urologic Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2011.07.068DOI Listing
December 2011

A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.

BJU Int 2011 Sep 13;108(5):679-86. Epub 2010 Dec 13.

Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1464-410X.2010.09947.x
Publisher Site
http://dx.doi.org/10.1111/j.1464-410X.2010.09947.xDOI Listing
September 2011

Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.

Oncology 2011 15;80(1-2):135-7; author reply 140-1. Epub 2011 Jun 15.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000327227DOI Listing
September 2011

Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma.

Cancer 2010 Oct;116(20):4696-702

Department of Urology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California 90025, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25279DOI Listing
October 2010

Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma.

J Urol 2010 Jun;183(6):2143-7

Department of Urology, University of California-Los Angeles, Los Angeles, California 90025-1738, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2010.02.023DOI Listing
June 2010

CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.

J Urol 2009 Aug 18;182(2):728-34. Epub 2009 Jun 18.

Department of Urology, University of California-Los Angeles, Los Angeles, California 90095-1738, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2009.03.077DOI Listing
August 2009

Functional and oncological outcomes of partial nephrectomy of solitary kidneys.

J Urol 2009 May 18;181(5):2037-42; discussion 2043. Epub 2009 Mar 18.

Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2009.01.024DOI Listing
May 2009

Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.

Cancer Epidemiol Biomarkers Prev 2009 Mar 24;18(3):894-900. Epub 2009 Feb 24.

Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, 10833 Le Conte Avenue, 66-118 CHS, Box 951738, Los Angeles, CA 90095-1738, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-08-0786DOI Listing
March 2009

Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.

J Clin Oncol 2009 Feb 5;27(5):746-53. Epub 2009 Jan 5.

Department of Urology, David Geffen School of Medicine at UCLA, Center for Health Sciences, Los Angeles, CA 90025-1738, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.15.8345DOI Listing
February 2009

Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.

Clin Cancer Res 2009 Feb;15(4):1162-9

Department of Urology, University of California at Los Angeles School of Medicine, Los Angeles, California 90095-1738, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-1229DOI Listing
February 2009

Pathobiology and prognosis of chromophobe renal cell carcinoma.

Urol Oncol 2008 Nov-Dec;26(6):604-9. Epub 2008 Jan 14.

Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2007.07.015DOI Listing
January 2009

Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

J Clin Oncol 2009 Jan 8;27(2):199-205. Epub 2008 Dec 8.

Department of Medicine, Division of Hematology & Oncology, University of California at Los Angeles, 2333D PVUB MC 705907, 10945 Le Conte Ave, Los Angeles, CA 90095-7059, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2008.17.7931
Publisher Site
http://dx.doi.org/10.1200/JCO.2008.17.7931DOI Listing
January 2009

Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.

Oncology 2008 14;75(3-4):215-23. Epub 2008 Oct 14.

University of California Los Angeles, Los Angeles, California 90095-7059, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000163850DOI Listing
November 2008

Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.

Cancer 2008 Oct;113(7):1641-8

Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095-1738, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23769DOI Listing
October 2008

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.

BJU Int 2008 Sep 10;102(6):692-6. Epub 2008 Apr 10.

Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2008.07660.xDOI Listing
September 2008

Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.

Cancer 2008 Sep;113(6):1324-31

Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095-1738, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.23708
Publisher Site
http://dx.doi.org/10.1002/cncr.23708DOI Listing
September 2008

Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.

Oncologist 2008 Sep 5;13(9):1021-9. Epub 2008 Sep 5.

Division of Hematology/Oncology, University of California at Los Angeles , California 90095-7059, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2008-0003DOI Listing
September 2008

Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas.

J Urol 2008 May 17;179(5):1719-26. Epub 2008 Mar 17.

Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California 90025-1738, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2008.01.018DOI Listing
May 2008

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.

Cancer Chemother Pharmacol 2008 Mar 16;61(3):515-24. Epub 2007 May 16.

David Geffen School of Medicine at the University of California, Los Angeles 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-007-0498-4DOI Listing
March 2008

The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma.

J Urol 2008 Jan 13;179(1):61-6. Epub 2007 Nov 13.

Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California 90095-1738, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S002253470702328
Publisher Site
http://dx.doi.org/10.1016/j.juro.2007.08.148DOI Listing
January 2008

Angiogenesis and angiogenic inhibitors in renal cell carcinoma.

Curr Urol Rep 2008 Jan;9(1):26-33

Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, 10945 LeConte Avenue, Suite 2333D, Box 957059, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
January 2008

Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.

Clin Cancer Res 2007 Dec;13(24):7388-93

Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0411DOI Listing
December 2007

Prognostic factors for renal cell carcinoma with tumor thrombus extension.

J Urol 2007 Oct 14;178(4 Pt 1):1189-95; discussion 1195. Epub 2007 Aug 14.

Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California 90095-1738, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2007.05.134DOI Listing
October 2007

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.

BJU Int 2007 Oct;100(4):765-9

University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2007.07121.xDOI Listing
October 2007

Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.

Oncology 2005 21;69 Suppl 3:17-24. Epub 2005 Nov 21.

Duke University Medical Centre, Durham, N.C. 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000088480DOI Listing
December 2005

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

J Clin Oncol 2005 Jun 28;23(16):3697-705. Epub 2005 Feb 28.

Division of Hematology/Oncology, UCLA School of Medicine, 10945 LeConte Ave, Suite 2338J, Los Angeles, CA 90095-7187, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.05.112DOI Listing
June 2005

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.

J Clin Oncol 2005 May;23(15):3502-8

Department of Medical Oncology and Transplantation, Room 25132, Morris Building, Box 3052, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.10.017DOI Listing
May 2005

Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?

Clin Colorectal Cancer 2004 Oct;4 Suppl 2:S69-73

Division of Hematology/Oncology, Department of Medicine, 10945 Le Conte Ave, University of California Los Angeles 2338 John, PVUB MC, 718707, Los Angeles, CA 90095-7187, USA.

View Article

Download full-text PDF

Source
October 2004

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.

Cancer 2004 Feb;100(4):746-50

Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.11956DOI Listing
February 2004

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.

Cancer 2003 May;97(9 Suppl):2381-6

Henry Singleton Brain Cancer Research Program, UCLA School of Medicine, Los Angeles, California 90095, USA.

View Article

Download full-text PDF

Source
http://neurooncology.ucla.edu/pub/4575.pdf
Web Search
http://doi.wiley.com/10.1002/cncr.11306
Publisher Site
http://dx.doi.org/10.1002/cncr.11306DOI Listing
May 2003

Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.

Cancer Res 2003 Jan;63(1):196-206

Department of Medicine, Division of Hematology and Oncology, University of California-Los Angeles, UCLA School of Medicine, Los Angeles, California 90095, USA.

View Article

Download full-text PDF

Source
January 2003

Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.

Am J Clin Oncol 2002 Apr;25(2):204-8

UCLA School of Medicine, Henry Singleton Brain Cancer Research Program, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00000421-200204000-00022DOI Listing
April 2002